Related Experiment Video
Updated: May 23, 2026

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1
1NF/TSC Cure Org., Melbourne, Australia.
Abstract:
Neurofibromatosis (NF) is a family of genetic diseases which are caused by dysfunction of either NF1 gene or NF2 gene. One in 3,000 people suffer from this tumor-carrying NF. NF1 gene product is a RAS GTPase activating protein (GAP) of 2,818 amino acids, which normally attenuates the GTP-dependent signal transducing activity of the G protein RAS. Dysfunction of this GAP leads to the abnormal activation of RAS, and eventually an oncogenic kinase called PAK1 as well. NF2 gene product is ''Merlin'' which directly inactivates PAK1. Thus, dysfunction of Merlin causes the abnormal activation of PAK1. In other words, dysfunction of NF1 gene (causing type 1 NF) is basically the same as dysfunction of NF2 gene (causing type 2 NF). In fact the growth of both NF1 and NF2 tumors requires PAK1, and all PAK1 blockers, synthetic chemicals or natural products, suppress the growth of these NF tumor cells both in vitro (cell culture) and in vivo (mice). However, until recently, no FDA-approved effective NF therapeutics is available on the market. Here a series of anti-PAK1 products shall be introduced, which would be potentially useful for the life-long treatment of NF patients in the future. These include the most potent HDAC (histone deacetylase) inhibitor FK228 (IC50: around 1 nM), that eventually blocks PAK1, the direct PAK1 inhibitor PF3758309 (IC50: around 10 nM), a CAPE (caffeic acid phenethyl ester)-based propolis extract called ''Bio 30'' from NZ (New Zealand), and an ARC (artepillin C)-based green propolis extract (GPE) from Brazil. Although the first two drugs are potent, none of them is available on the market as yet. The last two natural (bee-made) products are available on the market, and have been used for the therapy of NF and tuberous sclerosis (TSC) as well as many PAK1-dependent solid cancers such as breast and pancreatic cancers as well as glioma, which altogether represent more than 70% of all human cancers. Since PAK1 is not essential for the normal cell growth, propolis extracts cause no side effects.
Insights
Neurofibromatosis (NF) treatments targeting PAK1 show promise. Natural propolis extracts effectively suppress NF tumor growth with no side effects, offering a potential lifelong therapy for patients.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Neurofibromatosis (NF) comprises genetic disorders stemming from NF1 or NF2 gene dysfunction.
- Both NF1 and NF2 gene dysfunctions lead to the abnormal activation of the oncogenic kinase PAK1, crucial for tumor growth.
- Currently, no FDA-approved effective therapeutics exist for NF.
Purpose of the Study:
- To introduce a series of anti-PAK1 agents as potential lifelong treatments for NF patients.
- To evaluate the efficacy of synthetic and natural PAK1 inhibitors against NF tumors.
Main Methods:
- Investigated the role of PAK1 in NF1 and NF2 tumor cell growth in vitro and in vivo.
- Assessed the inhibitory effects of synthetic PAK1 blockers (FK228, PF3758309) and natural products (CAPE-based propolis extract 'Bio 30', ARC-based green propolis extract).
Main Results:
- All tested PAK1 blockers, including natural products, suppressed NF tumor cell growth.
- Propolis extracts (Bio 30 and GPE) are available and used for NF, TSC, and various PAK1-dependent cancers.
- PAK1 is not essential for normal cell growth, suggesting propolis extracts have no side effects.
Conclusions:
- Dysfunction of NF1 or NF2 genes converges on PAK1 activation, making it a therapeutic target for NF.
- Natural propolis extracts demonstrate significant potential for the long-term management of NF and other PAK1-driven cancers.
- The development of anti-PAK1 agents, particularly natural products, offers a promising therapeutic avenue for NF patients.
Related Concept Videos
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
